Table 2.
Inhibitory activity of cART drugs in the presence or absence of apabetalone on infection by HIV-1 clone strains
| Compounds | aInhibitory activity (mean ± SD) | |||||
|---|---|---|---|---|---|---|
| HIV-1NL4-3 (X4) | HIV-1SF162 (R5) | HIV-181A and NL4-3 (X4R5) | ||||
| EC50 (nM) | EC90 (nM) | EC50 (nM) | EC90 (nM) | EC50 (nM) | EC90 (nM) | |
| Zidovudine | 1.34 ± 0.17 | 14.80 ± 1.82 | 1.38 ± 0.13 | 8.05 ± 3.62 | 1.70 ± 0.35 | 23.40 ± 5.70 |
| Zidovudine + Apabetalone | 1.46 ± 0.20 | 26.92 ± 7.62 | 3.12 ± 0.11 | 34.02 ± 9.42 | 3.32 ± 0.64 | 35.74 ± 5.93 |
| Raltegravir | 0.18 ± 0.01 | 3.33 ± 0.76 | 0.09 ± 0.02 | 1.27 ± 0.56 | 0.13 ± 0.01 | 2.73 ± 0.32 |
| Raltegravir + Apabetalone | 0.15 ± 0.03 | 3.81 ± 0.43 | 0.02 ± 0.01 | 1.98 ± 0.18 | 0.07 ± 0.01 | 1.25 ± 0.44 |
| Nevirapine | 31.53 ± 11.43 | 179.00 ± 61.72 | 28.14 ± 6.35 | 157.34 ± 23.98 | 51.72 ± 11.52 | 214.38 ± 41.12 |
| Nevirapine + Aapbetalone | 23.77 ± 6.42 | 217.23 ± 64.57 | 35.71 ± 4.12 | 184.42 ± 35.91 | 45.07 ± 8.61 | 198.14 ± 27.33 |
| Maraviroc | / | / | 2.61 ± 0.46 | 12.80 ± 7.07 | 3.31 ± 0.84 | 41.88 ± 12.53 |
| Maraviroc + Apabetalone | / | / | 2.21 ± 0.18 | 12.25 ± 5.81 | 3.95 ± 0.45 | 48.21 ± 6.62 |
| Plerixafor | 10.38 ± 0.82 | 48.14 ± 8.77 | / | / | 18.14 ± 1.37 | 59.34 ± 8.39 |
| Plerxafor + Apabetalone | 9.22 ± 0.75 | 51.82 ± 4.97 | / | / | 20.38 ± 1.67 | 51.76 ± 5.44 |
Data were presented in means ± SD